Novel serum improves hair growth in androgenetic alopecia with no side effects

Key takeaways:

• 80% of participants reported an increase in hair growth, hair volume, scalp coverage and hair regrowth by week 8.
• There were no adverse events.

Revivv, a novel topical serum, led to meaningful improvements in hair growth with no adverse events in patients with androgenetic alopecia, according to a study.

Androgenetic alopecia (AGA) is a condition that effects 80% of men and up to 40% of women by the age of 70 years. This condition lacks treatment options with the only FDA-approved therapies being topical minoxidil or oral finasteride.

“Both drugs can curtail progressive hair loss and stimulate new hair growth, but their efficacies are inconsistent across the patient population and limited in mechanistic scope,” Jeffrey Rapaport, MD, FAAD, of Cosmetic Skin and Surgery Center and Hair-Therapy Hair Medical Clinic in Englewood Cliffs, New Jersey, and colleagues wrote. “Novel treatments that are either more effective or that are complementary to other lines of therapy are needed for the treatment of AGA.”

According to the study, Revivv is a novel serum including a proprietary blend of selected plant extracts and bioactives that has been created for AGA treatment.

Researchers evaluated this serum in an ethnically diverse, open-label, prospective, observational, real-world study conducted from January 2022 to June 2022 and found that Revivv improved hair growth.

During the 8 weeks of treatment, 150 participants (mean age, 56.4 years; 60% women), massaged Revivv with a roller into the frontal, crown and vertex areas of the scalp twice a day and left the application on overnight.

Eighty percent of participants reported an increase in hair growth, hair volume, scalp coverage and the amount of hair regrowth at week 8. Ninety percent also noticed an increased frequency of new hair and 100% reported decreased hair shedding. All participants further said Revivv was easy to use.

Seven patients participated in the phototrichogram substudy which showed statistically significant increases in hair thickness (~16% and ~15%; P < .05) and density (~25% and ~11%, P < .05) in the crown and vertex, respectively, at week 8 compared with baseline.

All participants reported that the product was easy to use and did not affect hair styling, and most expressed interest in continued use. Furthermore, the serum caused no adverse events.

“Larger clinical studies with a longer follow-up to evaluate efficacy are currently underway,” the authors concluded.